What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

被引:7
作者
Voorhies, Benjamin N. [1 ,2 ]
Stephens, Deborah M. [2 ]
机构
[1] Univ Utah, Dept Internal Med, Div Hematol & Hematol Malignancies, Salt Lake City, UT 84112 USA
[2] Univ Utah, Huntsman Canc Inst, 1950 Circle Hope,Room 3364, Salt Lake City, UT 84112 USA
关键词
Chronic lymphocytic leukemia; CLL review; CLL treatment; OPEN-LABEL; RITUXIMAB; IBRUTINIB; TRIAL; CYCLOPHOSPHAMIDE; MULTICENTER; FLUDARABINE; ABERRATIONS; VENETOCLAX; IDELALISIB;
D O I
10.1007/s11864-017-0450-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The front-line management of patients with chronic lymphocytic leukemia (CLL) has evolved significantly in recent years due to introduction of novel, targeted agents. Upon CLL diagnosis, physicians should determine whether treatment or careful observation is indicated. Once treatment is required, choice of therapy should be based on the age and fitness of the patient and the distinct molecular profile of their disease. As multiple novel agents are in various stages of development, all patients regardless of their age, fitness, and disease risk should be evaluated for clinical trial participation before initiating any front-line therapy. If no clinical trial is available, we provide our recommendations for front-line treatment of CLL patients. Healthy, young patients with low-risk disease (mutated IgVH, del (13q)) should be offered fludarabine, chlorambucil, and rituximab (FCR), while similar patients with high-risk disease (unmutated IgVH, del (17p), del (11q), and complex karyotype) should be considered for ibrutinib therapy. For those young, fit patients with high-risk disease and a contraindication to ibrutinib, FCR, or high-dose methylprednisolone and rituximab are options. In regard to older, unfit patients, a careful assessment of their fitness and ability to tolerate treatment should be undertaken before starting therapy. Those who have poor performance and multiple medical comorbidities should be considered for palliative care alone. However, those who are fit enough for treatment can be offered ibrutinib. If there is a contraindication to ibrutinib, they can be separated into low-and high-risk molecular groups. For the low-risk patients, bendamustine and rituximab or obinutuzumab and chlorambucil can be considered. For the high-risk patients, treatment
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Chronic lymphocytic leukemia at ASH 2017
    Wanner D.
    Steurer M.
    memo - Magazine of European Medical Oncology, 2018, 11 (2) : 105 - 108
  • [42] Updates from the 2017 American Society of Hematology annual meeting: practice-changing studies in untreated chronic lymphocytic leukemia
    Owen, C.
    Toze, C.
    Christofides, A.
    CURRENT ONCOLOGY, 2018, 25 (01) : 91 - 103
  • [43] Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?
    Brown, Jennifer R.
    HAEMATOLOGICA, 2018, 103 (07) : 1096 - 1098
  • [44] Novel therapy concepts for chronic lymphocytic leukemia
    Eichhorst, Barbara
    Hallek, Michael
    ONKOLOGE, 2016, 22 (04): : 283 - 292
  • [45] Recent advances in chronic lymphocytic leukemia therapy
    Uhm, Jieun
    BLOOD RESEARCH, 2020, 55 : 72 - 82
  • [46] Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints
    Cuneo, Antonio
    Cavazzini, Francesco
    Cavallari, Maurizio
    Foa, Robin
    Rigolin, Gian Matteo
    CANCER JOURNAL, 2021, 27 (04) : 320 - 327
  • [47] Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy
    Molica, Stefano
    Polliack, Aaron
    LEUKEMIA RESEARCH, 2016, 50 : 31 - 36
  • [48] Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia
    Shah, Neil P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) : 220 - +
  • [49] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
    Burger, J. A.
    Tedeschi, A.
    Barr, P. M.
    Robak, T.
    Owen, C.
    Ghia, P.
    Bairey, O.
    Hillmen, P.
    Bartlett, N. L.
    Li, J.
    Simpson, D.
    Grosicki, S.
    Devereux, S.
    McCarthy, H.
    Coutre, S.
    Quach, H.
    Gaidano, G.
    Maslyak, Z.
    Stevens, D. A.
    Janssens, A.
    Offner, F.
    Mayer, J.
    O'Dwyer, M.
    Hellmann, A.
    Schuh, A.
    Siddiqi, T.
    Polliack, A.
    Tam, C. S.
    Suri, D.
    Cheng, M.
    Clow, F.
    Styles, L.
    James, D. F.
    Kipps, T. J.
    Keating, Michael
    Jen, Jie
    Jindra, Pavel
    Simkovic, Martin
    Braester, Andrei
    Ruchlemer, Rosa
    Foa, Roberto
    Semenzato, Gianpietro
    Hawkins, Timothy
    Atanasio, Carolina Moreno
    Demirkan, Fatih
    Kaynar, Leylagul
    Pylypenko, Halyna
    Fox, Christopher
    Thirman, Michael
    Campbell, Philip
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) : 2425 - 2437
  • [50] Targeted Therapy in Chronic Lymphocytic Leukemia
    Kipps, Thomas J.
    Choi, Michael Y.
    CANCER JOURNAL, 2019, 25 (06) : 378 - 385